Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Drug:  lomustine
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Phase: Phase III
Type: Supportive care, Treatment
Age: 3 to 21 at diagnosis
Trial IDs: ACNS0331, NCI-2009-00335, CDR0000365506, COG-ACNS0331, NCT00085735
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Carboxyamidotriazole Orotate with or without Lomustine in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00047969, NCI-2014-00304, NCT01989052
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients with Previously Untreated HIV-Associated Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-068, NCI-2012-01695, 068, NCT01775475
ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: M14-483, NCI-2015-01199, 2014-004438-24, EORTC 1410-BTG, NCI-2015-01200, NCT02343406
Surgery and Combination Chemotherapy in Treating Younger Patients with Non-metastatic Standard-Risk Medulloblastoma
Phase: No phase specified
Type: Treatment
Age: 3 to 18
Trial IDs: J1403, NCI-2014-01870, CIR00004694, NA_00091840, NA_00091840 / CIR00004694, NCT02212574
Start Over